

Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis

SM Abdullah Al Mamun^{1*}, Rowshne Jahan², Quazi Tariqul Islam³, Tahera Nazrin⁴, Kahn Shajalal⁵

¹Senior Consultant & coordinator of Respiratory Medicine, Evercare Hospitals, Dhaka

²Consultant & of respiratory Medicine, Evercare Hospitals, Dhaka

³Professor & head of Internal medicine, Popular Medical College, Dhaka

⁴Consultant of pediatric Cardiology, Evercare hospitals, Dhaka

⁵Registrar of Respiratory Medicine, Evercare Hospitals, Dhaka

Retraction Note

The article entitled "Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis" has been accepted for publication in the Journal of Pulmonary & Respiratory Medicine considering the statements provided in the article as personal opinion of the author which was found not having any conflict or biasness towards anything.

Publisher took decision to make the article online solely based on the reviewer's suggestion which considered the article not but a personal opinion of the author. However, it is found that the author has some personal concerns and issues, therefore, being retracted from the journal.

***Address for Correspondence:** SM Abdullah Al Mamun, Senior Consultant & coordinator of Respiratory Medicine, Evercare Hospitals, Dhaka, E-mail: mamundr69@gmail.com

Copyright: © 2021 Mamun A, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received 10 December, 2020; **Accepted** 21 January, 2021 ; **Published** 29 January, 2021